Clolar Disease Interactions

Clofarabine injection may cause acute renal failure. Patients with infection, sepsis, or tumor lysis syndrome may be at increased risk of renal toxicity when treated with clofarabine injection. It is recommended to monitor patients for renal toxicity and interrupt or discontinue clofarabine injection as necessary.

Fatal and serious cases of enterocolitis, including neutropenic colitis, cecitis, and C. difficile colitis, have occurred during treatment with clofarabine. This has occurred more frequently within 30 days of treatment, and in the setting of combination chemotherapy. Enterocolitis may lead to necrosis, perforation, hemorrhage or sepsis complications. Monitor patients for signs and symptoms of enterocolitis and treat promptly. Care should be exercised when treating patients presenting with symptoms of enterocolitis.

Severe and fatal hepatotoxicity, including hepatitis and hepatic failure, has occurred with the use of clofarabine. Monitor hepatic function and for signs and symptoms of hepatitis and hepatic failure. It is recommended to discontinue clofarabine immediately for Grade 3 or greater liver enzyme and/or bilirubin elevation of the liver, or veno-occlusive disease is suspected. Care should be exercised when using this agent in patients with liver disease.

Clofarabine causes myelosuppression which may be severe and prolonged. Serious and fatal hemorrhage, including cerebral, gastrointestinal and pulmonary hemorrhage associated with thrombocytopenia has occurred. It is recommended to monitor complete blood counts including platelets and coagulation parameters and treat accordingly. Care should be exercised when using this agent in patients with bone marrow depression.

The use of clofarabine may cause acute renal failure. It is recommended to reduce the dose by 50% in patients with CrCl of 30 to 60 mL/min. At this time the manufacturer is not able to make a dosage recommendation in patients with CrCl less than 30 mL/min or in those on dialysis as there is insufficient information in this patient population. Care should be exercised when using this agent in patients with renal dysfunction.